I am a
Home I AM A Search Login

Papers of the Week

Papers: 3 Oct 2020 - 9 Oct 2020

Pharmacology/Drug Development



Prog Brain Res


Targeting the 5-HT and 5-HT receptors for acute migraine treatment.


Huang P-C, Yang F-C, Chang C-M, Yang C-P
Prog Brain Res. 2020; 255:99-121.
PMID: 33008517.


Migraine is a common and highly disabling headache disorder associated with a substantial socioeconomic burden. Migraine treatments can be categorized as preventive treatment, aimed at reducing the frequency and severity of migraine attacks, and acute therapy, intended to abort attacks. Traditionally, acute treatment can be classified as specific (ergot derivatives and triptans) or nonspecific (analgesics and nonsteroidal anti-inflammatory drugs). Triptans, a class of 5-HT receptor agonists with some affinity for the 5-HT receptor subtype, have been proven to be efficacious for acute treatment of moderate to severe migraine and have been deemed the gold standard. The availability of triptans in non-oral formulations, such as subcutaneous (SC) and intranasal forms, can be beneficial for patients who suffer from prominent nausea or vomiting, have a suboptimal response to oral agents, and/or seek a more rapid onset of treatment effects. However, triptans are contraindicated in patients with preexisting cardiovascular and/or cerebrovascular diseases due to their 5-HT-mediated vasoconstrictive action. For this reason, studies have focused on the development of ditans, a group of antimigraine drugs targeting 5-HT and 5-HT receptors. Unfortunately, 5-HT receptor agonists have been shown to be ineffective in the acute treatment of migraine. Several ditans targeting the 5-HT receptor have been developed and have shown no vasoconstrictive effect in preclinical studies, but only two of them, lasmiditan and LY334370, have been tested in clinical trials for migraine, and only lasmiditan has reached to Phase III clinical trials. These Phase III trials have demonstrated the efficacy and safety of lasmiditan, a selective 5-HT receptor agonist, in acute migraine treatment. Lasmiditan might offer an alternative migraine therapy without cardiovascular risks. This review will summarize the development of agents targeting the 5-HT and 5-HT receptors and the clinical evidence supporting the use of these agents for acute migraine treatment.